Estimates Revisions Alterity Therapeutics Limited Nasdaq
Stocks
ATHE
US02155X2053
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
16:30:00 2026-10-08 EDT
|
5-day change | 1st Jan Change | ||
| 3.070 USD | -7.53% |
|
-15.89% | -0.32% |
| 09-16 | Lake Street Initiates Alterity Therapeutics at Buy With $10 Price Target | MT |
| 08-30 | Alterity Therapeutics Enters Underwriting Agreement for Exercise of up to 8.4 Million Listed Options | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
Data source:
Alterity Therapeutics Limited(ATH)
EBIT - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
Data source:
Alterity Therapeutics Limited(ATH)
EBIT
Cash or Net Debt
- Stock Market
- Stocks
- ATH Stock
- ATHE Stock
- Consensus Alterity Therapeutics Limited
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
